Antitumour activity of oxaliplatin in neuroblastoma cell lines

European Journal of Cancer

Volumn 35, Issue 1, 1999, Pages 86-90

  Riccardi, A ^a   Ferlini, C ^a   Meco, D ^a   Mastrangelo, R ^a   Scambia, G ^a   Riccardi, R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antineoplastic agents; Apoptosis; Cell cycle block; Cisplatin; Neuroblastoma; Oxaliplatin

Indexed keywords

CISPLATIN; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CISPLATIN; HUMANS; NEUROBLASTOMA; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0032997671     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00342-6     Document Type: Article

References (19)

1. Rosemberg B., Van Camp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumor agents. Nature. 222:1969;385-386.
2. Ozols F.R., Ostchega Y., Curt G., Young R.C. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol. 5:1987;197-201.
3. Rixe O., Ortuzar W., Alvarez M., et al. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol. 52:1996;1855-1865.
4. Pendyala L., Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res. 53:1993;5970-5976.
5. Soulie P., Raymond E., Brienza S., Cvitkovic E. Oxaliplatin: the first DACH platinum in clinical practice. Bull Cancer. 84:1997;665-673.
6. Extra J.M., Espie M., Calvo F., Ferme C., Mignot L., Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 25:1990;299-303.
7. Chollet P., Bensmaine M.A., Brienza S., et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol. 7:(10):1996;1065-1070.
8. Cooper M.J., Hutchins G.M., Cohen P.S., Helman L.J., Israel M.A. Neuroblastoma cell lines mimic chromaffin neuroblastoma maturation. Prog Clin Biol Res. 366:1991;343-350.
9. Ferlini C., Di Cesare S., Rainaldi G., et al. A flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry. 24:1996;106-115.
10. Lund R.E., Lund J.R. Probabilities and upper quantiles for the studentized range. Applied Statistics. 32:1983;204-210.
11. Ferlini C., Scambia G., Distefano M., et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer. 75:(6):1997;884-891.
12. Degardin M., Cappelaere P., Krakowski I., Fargeot P., Cupissol D., Brienza S. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol. 32B:(4):1996;278-279.
13. Machover D., Diaz-Rubio E., de Gramont A., et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1:1996;95-98.
14. Evans A.E., D'Angio G.J., Propert K., Anderson J., Hann H.W. Prognostic factors in neuroblastoma. Cancer. 59:1987;1853-1859.
15. Stram D.O., Matthay K.K., O'Leary M., et al. Consolidation chemoradiotherapy and autologous bone marrow transplatation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent children's cancer group studies. J Clin Oncol. 14:1996;2417-2426.
16. Riccardi A., Servidei T., Tornesello A., et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer. 31A:(4):1995;494-499.
17. Los G., Mutsaers P.H., Ruevekamp M., et al. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett. 51:(2):1990;109-117.
18. Woynarowsky J.M., Chapman W.G., Napier C., Raymond E. Oxaliplatin (OxPt) effects on naked and intracellular DNA. Proc Amer Assoc Cancer Res. 38:1997;311(abstr 2083).
19. Fink D., Nebel S., Zheng H., et al. The role of mismatch repair in platinum drug resistance. Cancer Res. 56:(21):1996;4881-4886.